ABSTRACT
Thus, LIF appears to be an important regulator of human embryonic implantation by directly modulating trophoblast differentiation.
(J Clin Endocrinol Metab 81: [801] [802] [803] [804] [805] [806] 1996) L EUKEMIA inhibitory factor (LIF) is a glycoprotein that has multiple effects on different organ systems. It regulates the growth and differentiation of embryonic stem cells (1, 2), primordial germ cells (3), renal cells (4) peripheral neurons (51, osteoblasts (61, hepatocytes (7) , and adipocytes (8). Recent studies have shown LIF to be strongly associated with normal implantation in the mouse. In the murine uterus, Bhatt et al. (9) found that LIF was maximally expressed 4 days after fertilization, the day of implantation. Elegant studies by Stewart et al. (10) point to the functional significance of LIF during murine implantation. They found that transgenic mice lacking LIF could produce normal embryos, but the embryos failed to implant. When embryos from LIF-deficient mice were transferred to the uteri of wild-type mice, normal implantation occurred. The implantation blockade was partially corrected with the infusion of LIF into the peritoneal cavity of the LIF-deficient mice, suggesting that endometrially produced LIF is critical for murine implantation. Very little is known about the role of LIF in the human implantation process. We and others have recently determined that LIF is expressed in the human endometrium in a menstrual cycle dependent manner (11-13). We found maximal expression between days 19 and 25 of the menstrual cycle, coinciding with the time of human implantation. This temporal expression of LIF suggests a potential role for this cytokine in human implantation.
One possible mechanism for this role could involve the regulation of trophoblast function and differentiation.
In this study we have utilized purified cultures of human cytotrophoblasts to examine the effects of LIF on hCG secretion-a marker of villous syncytiotrophoblast differentiation-and on oncofetal fibronectin secretion-a marker of anchoring junctional trophoblast differentiation. Effect of LIF on hCG production by trophoblasts
Materials and Methods

Cytotrophoblast
The levels of hCG measured in the supernatants from cultured trophoblasts increased from 24 h to 72 h and plateaued at 96 h in both the LIF (10 ng/mL) treated and control groups. Very low levels of hCG were observed at 24 h in both groups (LIF: 0.68 + 0.02 [mean -t SD] mIU/mg DNA; control: 0.82 t 0.11 mIU/mg DNA). However, the levels of hCG in the LIF treated group were significantly lower than the control group at 48, 72, and 96 h. (P < 0.01 at 48 h; P < 0.005 at 72 and 96 h) (Fig. 1) . The difference was marked at 72 h: 35.3 2 8.5 mIU/mg DNA in the LIF treated group compared with 125.07 ? 7.2 mIU/mg DNA in the control group, a 3.5-fold difference. At 96 h, the level of hCG was 37.43 + 8.3 mIU/mg DNA in the LIF treated group compared with 178.45 I 18.4 mIU/mg DNA in the control group, a 4.8-fold difference. The inhibitory effect of LIF on the production of hCG was concentration-dependent between 0.01 and 1 ng/mL, but plateaued at higher concentrations (Fig. 2) . The effects of 10 and 100 ng/mL LIF on hCG secretion was not significantly different than the 1 ng/mL concentration. We also investigated whether this downregulation of hCG had occurred at the PhCG mRNA level. By Northern blot analysis we found that LIF treatment inhibited the expression of PhCG mRNA in trophoblasts in culture. The ratio of /3hCG/G3PDH mRNA was consistently lower in cells treated with LIF, with an average 50% decrease seen in four experiments (Fig. 3) . Effect of LIF on oncofetal fibronectin production by trophoblasts Treatment of trophoblasts in culture with LIF (10 ng/mL) led to increases in the levels of oncofetal fibronectin in a time-dependent manner. Although there was an increase in the oncofetal fibronectin secretion at 48 and 72 h, this increase was not statistically significant. At 96 h, there was an approximately 2-fold increase in the amount of oncofetal fibronectin secreted by the LIF treated trophoblasts (P < 0.007) (Fig. 4 ). LIF also increased the level of oncofetal fibronectin mRNA in cultured trophoblasts 2-fold (Fig. 5) 
Effect of LIF on the trophoblast morphology
Because LIF appeared to be shifting the differentiation of the trophoblasts away from an hCG secreting phenotype and towards a fibronectin secreting phenotype, we investigated whether LIF treated trophoblasts would exhibit improved JCE & M . 1996 Vol81. spreading on the culture surface as a result of an increased production of extracellular matrix (ECM) around the cells. Because increased cell-ECM interaction results in increased cell flattening, we evaluated this hypothesis by assessing the ratio of flat to round trophoblasts at 24 h intervals with or without added LIF. The ratio of flat to round cells increased starting from 48 h in the LIF (10 ng/mL) treated group compared with control group (P < 0.01 at 48 h; P < 0.005 at 72 and 92 h) (Fig. 6 ).
Discussion
Successful implantation depends upon a complex interaction between the developing blastocyst and the endometrium. It is known that for human implantation to occur, trophoblasts must attach to the underlying endometrial surface epithelium. The trophoblasts then interdigitate between the endometrial cells, travel through the basement membrane, and ultimately invade the maternal spiral arteries (21). The factors that control the intricate cascade of molecular and cellular events are beginning to be elucidated; however, they remain incompletely understood.
There is growing evidence that successful implantation depends upon regulation of growth factors and cytokines acting in an autocrine/paracrine fashion. These factors, in conjunction with steroid hormones, constitute maternalembryonic communication. Our developing understanding of human implantation has shown many similarities to the mouse. In this model, LIF has been shown to be one of the essential cytokines for implantation (10). A role for LIF in human implantation is suggested because we and others have found LIF in the human endometrium and have seen increased amounts of LIF in the secretory phase of the men- strual cycle (11-13). Relevant to these observations, LIF receptor mRNA expression has been found in human blastocysts (12). Therefore it seems likely that LIF is important for early uterine-blastocyst communication in the human, as shown in the mouse. While mouse and human implantation differ in some significant ways (most notably in that human implantation involves invasive trophoblasts and mouse does not), a common feature between mouse and human implantation is the necessity for tight attachment of the placenta to the uterine lining. While in the mouse LIF may function as the major cytokine that promotes the attachment of the blastocyst and the developing placenta to the uterus, in the human LIF may be one of several factors that serve this same function. One mechanism of LIF action could be through control of trophoblast differentiation. Depending on the external environment, undifferentiated cytotrophoblasts can differentiate along three pathways to become: 1) villous syncytiotrophoblasts, 2) extravillous anchoring trophoblasts, or 3) invasive intermediate trophoblasts (22) (Fig. 7) . There is growing evidence that growth factors and polypeptides may mediate these differentiation pathways (23). Biochemical and cellular markers of the trophoblast differentiation pathway have been established. The villous syncytiotrophoblast produces hCG as well as other essential pregnancy hormones (24). In vitro experiments have shown that CAMP (25-271, EGF (281, and hCG (29) direct cytotrophoblast differentiation towards a hormonally active syncytiotrophoblast phenotype and upregulate hCG production. The second type of differentiated trophoblast is the junctional trophoblast found where the chorionic villi make contact with the extracellular matrix (ECM). These cells form the anchoring cell columns seen at the junction of the placenta and the endometrium. Recently, a specific type of oncofetal fibronectin, trophouteronectin (TUN), has been identified at the tropho- The villous syncytiotrophoblast makes the majority of the placental hormones, the most studied being hCG. Cyclic AMP and its analogs, and more recently hCG itself (291, have been shown to direct cytotrophoblast differentiation towards a hormonally active syncytiotrophoblast phenotype. (Center) At the point where chorionic villi make contact with external extracellular matrix (decidual stromal ECM in the case of intrauterine pregnancies), a population of trophoblasts proliferates from the cytotrophoblast layer to form the second type of trophoblast-the junctional trophoblast. These cells form the anchoring cell columns that can be seen at the junction of the placenta and endometrium throughout gestation. Similar trophoblasts can be seen at the junction of the chorion layer of the external membranes and the decidua. The junctional trophoblasts make a unique fibronectin (trophouteronectin [TIJ'NI) that appears to mediate the attachment of the placenta to the uterus. TGF-/3, and now from our current work, leukemia inhibitory factor (LIF), has been shown to downregulate hCG svnthesis and umeaulate TIJN secretion. U&&t) Finallv. a third tvne of trophoblast hiff&entiates towards an invasive phenotype and leaves the placenta entirely-the invasive intermediate trophoblast. In addition to making human placental lactogen, these cells also make gelatinases, urokinase-type plasminogen activator (u-PA) and tvpe 1 plasminogen activator inhibitor (PAIIl.1). LIF, in addition to up>&-latina TUN nroduction and downreaulatine hCG secretion. has recently been-shown to also downresate triphoblast gelatin&tic activity (44).
blast-ECM junction and is thought to be a glycoprotein responsible for attachment of anchoring trophoblasts to the endometrium (30). TGF-P has been shown to increase TUN production while decreasing hCG production (15,311, stimulating trophoblast differentiation toward the anchoring phenotype. The third pathway leads to the development of invasive trophoblasts, which interdigitate through the extracellular spaces of the endometrium and penetrate the maternal spiral arteries. These trophoblasts produce a variety of proteases (3234) and protease inhibitor (35), which may mediate the invasive process. Unlike hCG, progesterone is produced and secreted by cytotrophoblasts as well as syncytiotrophoblasts (36), and is produced as early as 24 h by trophoblasts in cell culture (26). Thus progesterone secretion appears to be independent of the trophoblast differentiation pathway, and, consistent with this, we did not observe an effect of LIF on the progesterone production by cultured trophoblasts. We also found LIF did not affect the DNA content of trophoblasts, suggesting that LIF is not cytotoxic or mitogenic in this system.
Our results suggest that LIF may affect which differentiation pathway trophoblasts are directed towards. Exposure of cultured trophoblasts to LIF resulted in a decrease in /3hCG mRNA and protein with a concomitant increase in fibronectin mRNA and TUN secretion. This pattern of response to LIF suggests that this cytokine, like TGF-P (311, shifts the trophoblast differentiation pathway away from the hormonally active syncytiotrophoblast phenotype towards the anchoring junctional trophoblast phenotype. Recently, Sawai et al. (37) reported that LIF stimulates hCG production by trophoblasts. These investigators examined the effect of a short LIF exposure (150 min), while we examined the long-term effects of LIF (24-96 h). There may be a biphasic response to LIF, initially a stimulatory effect and thereafter an inhibitory effect as a result of cytotrophoblast differentiation; a similar phenomenon is observed for the effects of CAMP analogs on urokinase-type plasminogen activator (34). Although we have mostly used 10 ng/mL concentration of LIF to demonstrate its effect on trophoblast differentiation, we have also shown that this effect is observed at 0.01 ng/mL concentration, a physiologic dose secreted by stimulated endometrial stromal cells (11).
The pivotal role of LIFs ability to shift trophoblast differentiation towards a TUN-secreting anchoring phenotype is supported by our recent report of the expression of TUN by 4-8 cell human embryos (38) and the expression of an endometrial integrin (39) that may bind to this trophoblast fibronectin at the time of trophoblast penetration of the endometrium. The model that emerges from this work suggests that, as the early conceptus begins to implant into the endometrium, embryo-derived cytokines and growth factors, such as IL-1 (40), TNF-a! (41), PDGF (42), and TGF-/3 (43), further stimulate endometrial stromal cells to produce LIF (111, which in turn may induce the implanting trophoblasts to secrete increased amounts of TUN. This trophoblastendometrial positive feedback system may help to drive the implantation cascade, ensuring progressive attachment of the blastocyst to the endometrium. 
